341 related articles for article (PubMed ID: 12825572)
1. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin liposomal pegylated: new preparation. Breast cancer: not just a question of short-term cardiac effects.
Prescrire Int; 2004 Jun; 13(71):90-1. PubMed ID: 15233142
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.
Ventura GJ
J Clin Oncol; 2005 Apr; 23(12):2873; author reply 2873-4. PubMed ID: 15838014
[No Abstract] [Full Text] [Related]
4. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
5. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).
Leonard RC; Williams S; Tulpule A; Levine AM; Oliveros S
Breast; 2009 Aug; 18(4):218-24. PubMed ID: 19656681
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel: new preparation. No first-line use in metastatic breast cancer.
Prescrire Int; 2001 Dec; 10(56):178-9. PubMed ID: 11824441
[TBL] [Abstract][Full Text] [Related]
7. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
8. Role of pegylated liposomal doxorubicin in ovarian cancer.
Thigpen JT; Aghajanian CA; Alberts DS; Campos SM; Gordon AN; Markman M; McMeekin DS; Monk BJ; Rose PG
Gynecol Oncol; 2005 Jan; 96(1):10-8. PubMed ID: 15589573
[TBL] [Abstract][Full Text] [Related]
9. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group.
Findlay BP; Walker-Dilks C
Cancer Prev Control; 1998 Jun; 2(3):140-6. PubMed ID: 10093625
[TBL] [Abstract][Full Text] [Related]
10. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
[TBL] [Abstract][Full Text] [Related]
11. Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer.
Minisini AM; Andreetta C; Fasola G; Puglisi F
Expert Rev Anticancer Ther; 2008 Mar; 8(3):331-42. PubMed ID: 18366282
[TBL] [Abstract][Full Text] [Related]
12. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2010 Mar; (3):CD005006. PubMed ID: 20238335
[TBL] [Abstract][Full Text] [Related]
13. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
[TBL] [Abstract][Full Text] [Related]
14. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2010 May; 2010(5):CD005006. PubMed ID: 20464735
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
Jensen BV
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
[TBL] [Abstract][Full Text] [Related]
16. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
17. A case of manic episode during treatment with 5-fluorouracil, epirubicin and cyclophosphamide for breast cancer.
Pacchiarotti I; Mazzarini L; Pellegrini P; Venturelli V; Sani G; Sánchez-Moreno J; Mancinelli I; Tatarelli R; Kotzalidis GD; Girardi P
Gen Hosp Psychiatry; 2007; 29(5):461-3. PubMed ID: 17888816
[TBL] [Abstract][Full Text] [Related]
18. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
[TBL] [Abstract][Full Text] [Related]
19. Role of epirubicin in advanced breast cancer.
Conte PF; Gennari A; Landucci E; Orlandini C
Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S46-51. PubMed ID: 11970749
[TBL] [Abstract][Full Text] [Related]
20. Liposomal anthracyclines for breast cancer.
Sparano JA; Winer EP
Semin Oncol; 2001 Aug; 28(4 Suppl 12):32-40. PubMed ID: 11552228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
